Isis Chief Says Sanofi Likely to Reach Deal With Genzyme
From M&A Navigator (January 12, 2011)
Stanley Crooke, the chief executive of US drug developer Isis Pharmaceuticals (NASDAQ:ISIS), expects that French drug maker Sanofi-Aventis (EPA:SAN) will succeed in buying US rival Genzyme (NASDAQ:GENZ).
After its USD69 (EUR53.09) per share offer, valuing Genzyme at USD18.5bn, has been rejected, Sanofi-Aventis said it had re-launched discussions with the US drug maker on a "contingent value right", which would bring Genzyme shareholders additional earn-outs based on approvals and performance of the multiple sclerosis drug Lemtrada.
Crooke told Reuters in an interview today that this new proposal may help the French group to reach a deal.
Isis and Genzyme are working together to develop the experimental cholesterol drug mipomersen, which is likely to be a Genzyme and Sanofi drug, Crooke said, adding that Sanofi would bring additional strength to Genzyme to help develop its products.
Country: , USA
Target: Genzyme Corporation
Buyer: Sanofi-Aventis AS
Deal size in USD: 18.5bn
Type: Corporate acquisition
Status: Talks, Bidding
Comment: Isis’s CEO expects the takeover to succeed.
((Comments on this story may be sent to firstname.lastname@example.org))
Posted: January 2011